FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966406954> ?p ?o ?g. }

• W1966406954 endingPage "735" @default.
• W1966406954 startingPage "731" @default.
• W1966406954 abstract "Gefitinib (an epidermal growth factor receptor tyrosine kinase inhibitor) and bexarotene (a rexinoid) affect similar oncogenic pathways and are both metabolized through cytochrome P450 CYP3A4. We studied the combination of bexarotene and gefitinib in the third-line treatment of advanced non-small-cell lung cancer to examine pharmacokinetic interactions and establish the maximum tolerated dose. This was a single-institution, nonrandomized, open-label, phase I clinical trial with a standard 3+3 dose escalation. Three patients were enrolled at each dose level on the basis of pharmacokinetic analysis with dose level 1 including gefitinib (Iressa) 250 mg oral daily and bexarotene (Targretin) 400 mg/m2 oral daily and dose level +1 including gefitinib 500 mg oral daily and bexarotene 400 mg/m2 oral daily. Patients received gefitinib alone for 2 weeks to allow for steady state and thereafter, bexarotene was added. In dose level 1, two of three patients had undetectable gefitinib levels at day 15 for unknown reasons. However, the peak levels on day 29 for all three patients receiving 250 mg of gefitinib with bexarotene are lower than published peak levels. Among the three patients in dose level +1, ∼40% lower gefitinib plasma concentrations were noted on day 29 compared with day 15 along with a mean 44% reduction in area under the plasma concentration–time curve from 0 to 24 h (AUC0–24). Bexarotene appears to lower the Cmax and AUC0–24 of gefitinib through cytochrome P450 CYP3A4. Our results have pharmacokinetic implications for ongoing trials that combine bexarotene with other small molecules in the era of personalized cancer therapy." @default.
• W1966406954 created "2016-06-24" @default.
• W1966406954 creator A5035640724 @default.
• W1966406954 creator A5054133895 @default.
• W1966406954 creator A5064826824 @default.
• W1966406954 creator A5072229684 @default.
• W1966406954 creator A5074095670 @default.
• W1966406954 creator A5087686762 @default.
• W1966406954 date "2013-08-01" @default.
• W1966406954 modified "2023-10-18" @default.
• W1966406954 title "Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer" @default.
• W1966406954 cites W1599750485 @default.
• W1966406954 cites W1899283284 @default.
• W1966406954 cites W1968787851 @default.
• W1966406954 cites W1969525589 @default.
• W1966406954 cites W1985059561 @default.
• W1966406954 cites W1989410548 @default.
• W1966406954 cites W1989476306 @default.
• W1966406954 cites W2023489093 @default.
• W1966406954 cites W2044562269 @default.
• W1966406954 cites W2057136240 @default.
• W1966406954 cites W2108885325 @default.
• W1966406954 cites W2108947370 @default.
• W1966406954 cites W2112263503 @default.
• W1966406954 cites W2115782311 @default.
• W1966406954 cites W2118269736 @default.
• W1966406954 cites W2118274595 @default.
• W1966406954 cites W2120718661 @default.
• W1966406954 cites W2126314379 @default.
• W1966406954 cites W2132596019 @default.
• W1966406954 cites W2137836990 @default.
• W1966406954 cites W2138047541 @default.
• W1966406954 cites W2139248078 @default.
• W1966406954 cites W2142661339 @default.
• W1966406954 cites W2145295538 @default.
• W1966406954 cites W2146404049 @default.
• W1966406954 cites W2153477391 @default.
• W1966406954 cites W2162565810 @default.
• W1966406954 cites W2163147844 @default.
• W1966406954 cites W2167368130 @default.
• W1966406954 cites W2171336746 @default.
• W1966406954 doi "https://doi.org/10.1097/cad.0b013e32836100d7" @default.
• W1966406954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23552470" @default.
• W1966406954 hasPublicationYear "2013" @default.
• W1966406954 type Work @default.
• W1966406954 sameAs 1966406954 @default.
• W1966406954 citedByCount "9" @default.
• W1966406954 countsByYear W19664069542014 @default.
• W1966406954 countsByYear W19664069542018 @default.
• W1966406954 countsByYear W19664069542020 @default.
• W1966406954 countsByYear W19664069542021 @default.
• W1966406954 countsByYear W19664069542022 @default.
• W1966406954 countsByYear W19664069542023 @default.
• W1966406954 crossrefType "journal-article" @default.
• W1966406954 hasAuthorship W1966406954A5035640724 @default.
• W1966406954 hasAuthorship W1966406954A5054133895 @default.
• W1966406954 hasAuthorship W1966406954A5064826824 @default.
• W1966406954 hasAuthorship W1966406954A5072229684 @default.
• W1966406954 hasAuthorship W1966406954A5074095670 @default.
• W1966406954 hasAuthorship W1966406954A5087686762 @default.
• W1966406954 hasConcept C104317684 @default.
• W1966406954 hasConcept C112705442 @default.
• W1966406954 hasConcept C121608353 @default.
• W1966406954 hasConcept C126322002 @default.
• W1966406954 hasConcept C143998085 @default.
• W1966406954 hasConcept C185592680 @default.
• W1966406954 hasConcept C22979827 @default.
• W1966406954 hasConcept C2776256026 @default.
• W1966406954 hasConcept C2778820342 @default.
• W1966406954 hasConcept C2778820923 @default.
• W1966406954 hasConcept C2779438470 @default.
• W1966406954 hasConcept C2780580887 @default.
• W1966406954 hasConcept C55493867 @default.
• W1966406954 hasConcept C63932345 @default.
• W1966406954 hasConcept C71924100 @default.
• W1966406954 hasConcept C86339819 @default.
• W1966406954 hasConcept C98274493 @default.
• W1966406954 hasConceptScore W1966406954C104317684 @default.
• W1966406954 hasConceptScore W1966406954C112705442 @default.
• W1966406954 hasConceptScore W1966406954C121608353 @default.
• W1966406954 hasConceptScore W1966406954C126322002 @default.
• W1966406954 hasConceptScore W1966406954C143998085 @default.
• W1966406954 hasConceptScore W1966406954C185592680 @default.
• W1966406954 hasConceptScore W1966406954C22979827 @default.
• W1966406954 hasConceptScore W1966406954C2776256026 @default.
• W1966406954 hasConceptScore W1966406954C2778820342 @default.
• W1966406954 hasConceptScore W1966406954C2778820923 @default.
• W1966406954 hasConceptScore W1966406954C2779438470 @default.
• W1966406954 hasConceptScore W1966406954C2780580887 @default.
• W1966406954 hasConceptScore W1966406954C55493867 @default.
• W1966406954 hasConceptScore W1966406954C63932345 @default.
• W1966406954 hasConceptScore W1966406954C71924100 @default.
• W1966406954 hasConceptScore W1966406954C86339819 @default.
• W1966406954 hasConceptScore W1966406954C98274493 @default.
• W1966406954 hasIssue "7" @default.
• W1966406954 hasLocation W19664069541 @default.
• W1966406954 hasLocation W19664069542 @default.
• W1966406954 hasOpenAccess W1966406954 @default.

• next